However, in vitro analysis of the effect of curcumin on LS180 cells for P-glycoprotein (P-gp) induction/inhibition and CYP3A4 inhibition in a single platform showed curcumin should not be administered with bedaquiline (TMC-207), a recently approved drug for the treatment of multidrug-resistant tuberculosis (MDRTB), because both bedaquiline and curcumin are substrates for both P-gp and CYP3A4 [59]. The gene discussed is ABCB1; the disease is multidrug-resistant tuberculosis.